BAXTER INTERNATIONAL INC acquired Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) for $60 million upfront purchase price (including acquired inventory) plus up to $30 million additional contingent consideration (acquisition-date fair value $24 million), a transaction completed in March 2021, structured as all cash (with contingent consideration). The deal was a Asset purchase.
Transderm Scop (TDS) rights (from subsidiaries of GlaxoSmithKline) operates in Pharmaceuticals, is based in Rights for the U.S. and specified ex-US territories (acquired from GlaxoSmithKline subsidiaries). Transderm Scop (TDS) is a transdermal patch used to prevent nausea and vomiting in the U.S. and motion sickness in European markets; Baxter acquired the rights for the U.S. and specified territories outside the U.S. from subsidiaries of GlaxoSmithKline.
Expands Baxter's pharmaceuticals portfolio with an established branded transdermal product.
Established branded transdermal product expanding Baxter's pharmaceuticals portfolio. Integrated into Baxter's pharmaceuticals business
On March 31, 2021, we acquired the rights to Transderm Scop (TDS) for the U.S. and specified territories outside of the U.S. from subsidiaries of GlaxoSmithKline for an upfront purchase price of $60 million including the cost of acquired inventory and the potential for additional cash consideration of $30 million, which had an acquisition-date fair value of $24 million.Baxter FY2021 10-K, Acquisitions note
Advisory firms were not disclosed for this transaction.